83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)

Abstract

Listen

Translate article

Weight loss (WL) with semaglutide 2.4 mg vs. placebo (PBO) in the STEP 2 trial was analyzed according to baseline characteristics. STEP 2 was a 68-week RCT (NCT03552757). Adults (N=1210) with BMI ≥27 kg/m2 and type 2 diabetes (T2D; HbA1c 7-10% [53-86 mmol/mol]) were randomized to once‑weekly s.c. semaglutide 2.4 mg, 1.0 mg (data not shown) or PBO. Categorical WL was evaluated at week 68 by baseline age, sex, race, body weight (BW), HbA1c, and diabetes therapy. The odds of achieving WL ≥5% or ≥10% for these parameters were compared using post-hoc logistic regression analyses (not controlled for multiplicity). At week 68, the proportions of patients (pts) with WL ≥5% and ≥10% were 73.2% and 49.9% for semaglutide 2.4 mg vs. 27.6% and 7.1% for PBO. Pts were significantly more likely to achieve WL ≥5% or ≥10% with semaglutide 2.4 mg vs. PBO in most subgroups (Table). There were no significant interactions for any subgroups, except sex; the odds ratios for achieving WL ≥5% or ≥10% with semaglutide 2.4 mg vs. PBO were more than double for females vs. males (p Disclosure I. Lingvay: Advisory Panel; Self; Bayer Healthcare Pharmaceuticals Inc., Lilly Diabetes, Consultant; Self; TARGET PharmaSolutions, Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk, Pfizer Inc., Zealand Pharma A/S, Research Support; Self; Mylan N. V., Sanofi. W. Garvey: None. L. Faerch: Employee; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S. A. Koroleva: Employee; Self; Novo Nordisk A/S. R. F. Kushner: Advisory Panel; Self; Novo Nordisk A/S. C. Le roux: Advisory Panel; Self; Boehringer Ingelheim International GmbH, GI Dynamics, Herbalife International of America, Inc., Johnson & Johnson, Medtronic, Novo Nordisk A/S. S. Lim: None. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. T. A. Wadden: Advisory Panel; Self; Novo Nordisk, Weight Watchers International, Inc. S. O. R. Wallenstein: Employee; Self; Novo Nordisk. Funding Novo Nordisk A/S